公司概述
InflaRx N.V. operates as a clinical-stage biopharmaceutical entity focused on discovering and developing inhibitors utilizing C5a technology platforms within both Germany and the United States. This strategic positioning places the company squarely within the Healthcare sector, specifically the Biotechnology industry, where it targets the treatment of various autoimmune and other inflammatory diseases through its proprietary inflammatory mediator approach. The company's current scale is characterized by a market capitalization of $74.46M, an annualized revenue of $29,331 over the trailing twelve months, and an organizational structure comprising 65 employees. These valuation and revenue metrics collectively indicate that the firm operates as a small-cap biotechnology player with significant investment risk, as its substantial market cap relative to its negligible revenue suggests the market is pricing in future clinical development potential rather than current operational profitability.
财务健康
The company reported revenue of $29,331 and a net income of $-45,633,780 for the trailing twelve months, while EBITDA stood at $-48,198,212, revealing a cost structure dominated by heavy research and development expenditures that far exceed current sales. Free cash flow is recorded at $-14,833,020, indicating that the company is consuming cash reserves to fund its clinical-stage operations rather than generating liquidity from its core business activities. The margin profile is anomalous and indicative of early-stage financial reporting, with a gross margin of 0.0%, a profit margin of 0.0%, and an operating margin listed as 37898.3%, which typically reflects accounting adjustments or lack of meaningful operating revenue in the context of biotech startups. Liquidity analysis shows the company holds $46.46M in cash against $897,916 in debt, resulting in a debt-to-equity ratio of 2.16, which suggests a highly leveraged balance sheet relative to equity despite the absolute dollar amount of debt being low. The current ratio of 4.13 indicates that the company possesses more than four dollars of current assets for every dollar of current liabilities, pointing to strong short-term liquidity coverage. Return on Equity stands at -88.6% and Return on Assets is -46.0%, metrics that reveal management is currently generating negative returns on capital due to the company's inability to monetize its R&D investments into net profit at this stage of development.
估值评估
The trailing twelve-month P/E ratio is listed as N/A due to the lack of positive earnings, while the forward P/E is calculated at -1.37, implying that expected future earnings are projected to remain negative or are not yet material enough to support a standard valuation multiple. The price-to-book ratio is 1.55, suggesting the market values the company at a 55% premium over its net asset book value, a common phenomenon in biotechnology where intangible intellectual property and clinical pipeline value are not fully captured on the balance sheet. Alternative valuation metrics include a price-to-sales ratio of 2538.67 and an EV/EBITDA of -0.60, figures that suggest the company is valued almost exclusively on speculative future growth expectations rather than current cash flow or sales performance. The stock price has fluctuated between a 52-week high of $1.94 and a 52-week low of $0.71, with the current trading position dependent on the real-time market price but historically constrained within this specific volatility band. The beta value is 1.51, indicating that the stock exhibits significantly higher price volatility than the broader market, moving approximately 51% more aggressively in response to market-wide movements.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, reflecting the fact that the company is a clinical-stage entity where historical growth rates are not applicable due to the lack of a sustained revenue history. Since the company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, it follows a standard biotechnology model of reinvesting all available capital and cash flow back into research, clinical trials, and platform development rather than distributing income to shareholders. Consequently, the company's growth profile is entirely dependent on the successful advancement of its lead product candidate, vilobelimab, and the generation of future revenue to eventually transform from a cash-burning entity to a profitable one. The overall financial picture presents a classic early-stage biotech profile with no current income generation and growth metrics that cannot be quantified by traditional percentage-based historical data.